Technical Bulletin: Side-by-Side Evaluation of Three Leading Mixing Technologies for the Fabrication and Scale-Up of LNP-based Therapeutics.
Our team looks forward to seeing at this conference. Book a meeting with us at bd@phosphorex.com or swing by our booth #30!
The American Society of Gene and Cell Therapy's (ASGCT) Annual Meeting is the premier event for professionals in gene and cell therapy. Email bd@phosphorex.com to book a meeting with us. Or stop by our booth # 835!
Industry's Largest & Most Renowned Event to Accelerate Your Oligo and Peptide Therapeutics to Market: Leading Strategies for Expediting R&D and Improving CMC Efficiency. Email bd@phosphorex.com to schedule a meeting with our BD Director, Evan.
The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. Email bd@phosphorex.com to book a meeting today! Stop by our booth # 6044 !
Partnership Opportunities in Drug Delivery Editor interviews Jarlath Keating, CEO of Phoshorex . Article entitled "CDMO Innovations to Facilitate New Therapeutics Development"
Webinar featuring our Formulation Scientist, Sydney Marchando, MS. & Nick Boylan, Ph.D., Director of Nucleic Acid Delivery.
Glioblastoma (GBM) is a malignant brain tumor that remains among the most formidable cancers.Despite a well-established standard of care of maximal surgical resection followed by radiotherapy plus concomitant temozolomide (TMZ), median survival remains approximately 15 months.
Our team presents the process of Nanosuspension for the novel Indirubin, for the potential treatment of Glioblastoma.
Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug delivery technologies that could improve the delivery of various types of drugs. This can include proteins, peptid
Phosphorex's director of nucleic delivery presents on Nanoparticles for the delivery of ASO to the CNS
In collaboration with Brown University, Phosphorex presents on the use the nanoparticle formulation, to enable Systematic Delivery of Tx Agent to treat GBM
Phosphorex, an Ampersand Capital Partners company, and drug delivery-focused contract development and manufacturing organization ("CDMO"), announced today the appointment of David Tammaro as Chief Financial Officer.